(4-Chlorophenyl){1-[2-(isobutylamino)ethyl]-4piperidinyl}methanone | 298697-53-7

• 英文名称: (4-Chlorophenyl){1-[2-(isobutylamino)ethyl]-4piperidinyl}methanone
• 英文别名: (4-Chlorophenyl)(1-(2-(isobutylamino)ethyl)piperidin-4-yl)methanone；(4-chlorophenyl)-[1-[2-(2-methylpropylamino)ethyl]piperidin-4-yl]methanone
• CAS: 298697-53-7
• 化学式: C₁₈H₂₇ClN₂O
• 分子量: 322.878
• InChiKey: CCEKWQBFPXXKBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Novel compounds
  申请人：AstraZeneca AB, a Sweden corporation

  公开号：US20030134840A1

  公开（公告）日：2003-07-17

  The invention provides compounds of general formula 1 wherein R 1 , m, Q, T, n, R 2 , R 3 , V, W, X and R 4 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了一般式1的化合物，其中R1、m、Q、T、n、R2、R3、V、W、X和R4在说明书中定义，其制备方法，包含它们的制药组合物以及它们在治疗中的应用。
• Methods and compositions for preventing and treating auditory dysfunctions
  申请人：United States Government as represented by the Department of Veterans Affairs

  公开号：US10987333B2

  公开（公告）日：2021-04-27

  The invention provides methods for treating auditory impairments in a subject in need of treatment comprising administering to said subject an effective amount of a composition comprising, as an active agent, one or more of a carboxy alkyl ester, a quinic acid derivative, a caffeic acid derivative, a ferulic acid derivative, or a quinic acid lactone or derivative thereof or pharmaceutically acceptable salt thereof and an acceptable carrier or excipient, so as to treat auditory impairments in the subject.

  本发明提供了治疗需要治疗的受试者听觉障碍的方法，包括向所述受试者施用有效量的组合物，该组合物作为活性剂包含羧基烷基酯、喹酸衍生物、咖啡酸衍生物、阿魏酸衍生物或喹酸内酯或其衍生物或其药学上可接受的盐中的一种或多种，以及可接受的载体或赋形剂，从而治疗受试者的听觉障碍。
• Method for detecting single nucleotide polymorphisms (SNP'S) and point mutations
  申请人：PharmacoGenetics, Ltd.

  公开号：US20030017487A1

  公开（公告）日：2003-01-23

  A method of genotyping single nucleotide polymorphisms (“SNP”) and point mutations in nucleic acid based on chain extension by polymerase. This invention is based on the fact that the nucleoside immediately 5′ adjacent to any SNP/point mutation site is known, and the neighboring sequence immediately 3′ adjacent to the site is also known. A primer complementary to the sequence directly adjacent to the SNP on the 3′ side in a target polynucleotide is used for chain elongation. The polymerase reaction mixture contains one chain-terminating nucleotide having a base complementary to the nucleotide directly adjacent to the SNP on the 5′ side in the target polynucleotide. An additional dNTP may be added to produce a primer with the maximum of a two-base extension. The resultant elongation/termination reaction products are analyzed for the length of chain extension of the primer, or for the amount of label incorporation from a labeled form of the terminator nucleotide.

  一种基于聚合酶链延伸对核酸中单核苷酸多态性（"SNP"）和点突变进行基因分型的方法。本发明基于以下事实：与任何 SNP/点突变位点紧邻 5′的核苷是已知的，与该位点紧邻 3′的邻接序列也是已知的。与目标多核苷酸 3′侧 SNP 直接相邻序列互补的引物用于核苷酸链的延伸。聚合酶反应混合物中含有一个链终止核苷酸，该核苷酸的碱基与目标多核苷酸 5′侧与 SNP 直接相邻的核苷酸互补。可添加额外的 dNTP，以产生最大延伸两个碱基的引物。对由此产生的延伸/终止反应产物进行分析，以确定引物的链延伸长度或终止核苷酸标记形式的标记结合量。
• NOVEL COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1165545A1

  公开（公告）日：2002-01-02
• JP2002540204A
  申请人：——

  公开号：JP2002540204A

  公开（公告）日：2002-11-26